What is the recommended protocol for using atosiban (oxytocin/vasopressin receptor antagonist) in women with preterm labor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Atosiban Protocol for Women with Preterm Labor

Atosiban is an effective tocolytic agent for delaying delivery in women with preterm labor, with a better maternal safety profile than beta-agonists and should be administered according to a three-step protocol: initial bolus followed by high-dose infusion, then maintenance infusion. 1, 2

Indications for Atosiban

  • Atosiban is indicated for women between 24-34 weeks gestation with preterm labor to delay delivery for 48-72 hours, allowing time for administration of antenatal corticosteroids and maternal transfer to a tertiary care facility 3
  • The primary goal of tocolytic therapy is not to prevent preterm birth entirely but to gain time for interventions that improve neonatal outcomes 3
  • Atosiban has demonstrated effectiveness in delaying delivery in women as early as 18-24 weeks gestation 4

Administration Protocol

Initial Treatment (Acute Tocolysis)

  • Step 1: Administer intravenous bolus dose of 6.75 mg 1, 5
  • Step 2: Follow with high-dose intravenous infusion of 300 μg/min for 3 hours 1, 5
  • Step 3: Continue with maintenance intravenous infusion of 100 μg/min for up to 48 hours 1, 5

Maintenance Therapy (If Needed)

  • After successful acute tocolysis, maintenance therapy can be considered 6
  • Administer as continuous subcutaneous infusion via pump at 30 μg/min 6
  • Continue maintenance therapy until 36 weeks' gestation 6

Efficacy and Monitoring

  • Tocolytic effect typically begins within 3-10 minutes (median: 6.5 minutes) 4
  • Complete cessation of contractions usually occurs within 3-12 hours (median: 7.5 hours) 4
  • Monitor for:
    • Uterine contractions (frequency and intensity) 1, 2
    • Maternal vital signs 1, 2
    • Fetal heart rate 1, 2

Safety Profile and Advantages

  • Atosiban has a more favorable maternal safety profile compared to beta-agonists like salbutamol and ritodrine 1, 5
  • Significantly fewer maternal cardiovascular side effects compared to beta-agonists (4.0% vs 84.3%) 5
  • Lower rate of treatment discontinuation due to adverse events compared to other tocolytics 2, 5
  • Neonatal outcomes are comparable to other tocolytic agents 1, 5

Important Considerations

  • Atosiban is as effective as beta-agonists in delaying preterm birth for at least 48 hours 1, 5
  • Consider concurrent administration of antenatal corticosteroids for fetal lung maturity when gestational age is ≤34 weeks 3
  • For deliveries before 36 weeks gestation, antenatal corticosteroids are recommended to reduce the risk of respiratory distress syndrome 7
  • In cases of preterm labor before 32 weeks, consider magnesium sulfate for fetal neuroprotection 8

Contraindications and Cautions

  • Atosiban should not be used when continuation of pregnancy is contraindicated 1
  • Use with caution in multiple gestations 5
  • Monitor for injection site reactions during maintenance therapy 6

Clinical Pitfalls to Avoid

  • Remember that no tocolytic has been consistently shown to improve neonatal outcomes or reduce the overall rate of preterm birth - the main benefit is gaining time for corticosteroid administration and maternal transfer 3
  • Do not continue tocolysis when delivery would be beneficial for maternal or fetal indications 3
  • Avoid using atosiban as a long-term solution for preventing preterm birth without addressing underlying causes 3

References

Research

Atosiban versus usual care for the management of preterm labor.

Journal of perinatal medicine, 2007

Guideline

Tocolytics for Delaying Preterm Birth

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fetal Neuroprotection in Premature Rupture of Membranes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.